AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22428515 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of fentanyl added to 2.5 mls of 0.5% hyperbaric bupivacaine intrathecally
Number of subjects: 60
Study 22428515 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mls of 0.5% hyperbaric bupivacaine intrathecally
Number of subjects: 60
Study 19620953 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 10
Study 19620953 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 17445897 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ
Number of subjects: 120
Study 17445897 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT
Number of subjects: 120
Study 17445897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensar AR40
Number of subjects: 120
Study 15372170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 35
Study 11354524 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A Behavior Pattern (TABP) classification using Structured Interview (SI)
Number of subjects: 44
Study 11354524 — intervention group
Group type: COMPARATOR
Intervention: Incremental cycling test
Number of subjects: 44
Study 10668412 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-101,606 (0.75 mg/kg/hr for 2 hours, then 0.37 mg/kg/hr for 22 or 70 hours)
Number of subjects: 53
Study 10668412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 7787152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Twin bag system
Number of subjects: 82
Study 7787152 — intervention group
Group type: COMPARATOR
Intervention: Ultra Y-set system
Number of subjects: 82
Study 2110537 — intervention group
Group type: EXPERIMENTAL
Intervention: Morniflumate suppositories (400 mg, twice daily for 4 days)
Number of subjects: 101
Study 2110537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 4 days)
Number of subjects: 101
Study 6772048 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 46
Study 6772048 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 46
Study 6772048 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolept anaesthesia
Number of subjects: 46
Study 31115111 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic factor VIII (FVIII) concentrate
Number of subjects: 0
Study 31115111 — intervention group
Group type: COMPARATOR
Intervention: Episodic treatment for bleeding
Number of subjects: 0
Study 27893480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed resistance training
Number of subjects: 14
Study 25239479 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐EPI equation
Number of subjects: 6083
Study 25239479 — intervention group
Group type: COMPARATOR
Intervention: MDRD equation
Number of subjects: 6083
Study 23604336 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 20
Study 23604336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21955465 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Internet intervention with a large online social network
Number of subjects: 1326
Study 19996674 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group implants placed 2 mm supracrestally
Number of subjects: 26
Study 19996674 — intervention group
Group type: COMPARATOR
Intervention: Control group implants positioned at bone level
Number of subjects: 26
Study 17196489 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch blocks
Number of subjects: 26
Study 17196489 — intervention group
Group type: COMPARATOR
Intervention: Pericapsular blocks
Number of subjects: 26
Study 15145175 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-photon radiotherapy, mean prescribed dose 76.3 CGE
Number of subjects: 85
Study 11773293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for 1-3 years
Number of subjects: 0
Study 11773293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for 5 years
Number of subjects: 0
Study 11773293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for longer than 5 years
Number of subjects: 0
Study 11773293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing tamoxifen duration trials (aTTom and ATLAS)
Number of subjects: 0
Study 11773293 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to other hormonal interventions after 5 years of tamoxifen
Number of subjects: 0
Study 11385383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 70
Study 11385383 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients undergoing urologic surgery
Number of subjects: 70
Study 9363342 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph (HRT) optic disc shape measures
Number of subjects: 226
Study 8498876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 75
Study 8498876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 75
Study 8498876 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy (BT)
Number of subjects: 75
Study 2888017 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (30 mg/kg bolus followed by 5 mg/kg/hour infusion for 9 hours)
Number of subjects: 223
Study 2888017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 2888017 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 223
Study 2196240 — intervention group
Group type: EXPERIMENTAL
Intervention: TBF + R administered in 3 office visits over 8 weeks
Number of subjects: 76
Study 2196240 — intervention group
Group type: EXPERIMENTAL
Intervention: TBF + R plus instruction in cognitive stress coping techniques administered in 5 office visits over 8 weeks
Number of subjects: 76
Study 2196240 — intervention group
Group type: COMPARATOR
Intervention: HA monitoring (control group)
Number of subjects: 76
Study 5324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol plus amphetamine
Number of subjects: 0
Study 5324976 — intervention group
Group type: COMPARATOR
Intervention: Ethanol plus placebo
Number of subjects: 0
Study 5324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 5324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 5324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-amphetamine
Number of subjects: 0
Study 5324976 — intervention group
Group type: COMPARATOR
Intervention: Ethanol-lactose
Number of subjects: 0
Study 31487195 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sRAGE
Number of subjects: 393
Study 27524498 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous Testosterone
Number of subjects: 121
Study 27524498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 26206666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized racemic salbutamol solution
Number of subjects: 112
Study 26206666 — intervention group
Group type: COMPARATOR
Intervention: 3% sodium chloride (NaCl) solution
Number of subjects: 112
Study 23612695 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 407
Study 23612695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping of the membranes
Number of subjects: 407
Study 23612695 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Sweeping
Number of subjects: 407
Study 23612695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 407
Study 21788033 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240/80 mg
Number of subjects: 125
Study 21788033 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide to Degarelix (240/80 mg or 240/160 mg)
Number of subjects: 125
Study 21788033 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (continuation)
Number of subjects: 125
Study 19364237 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) with attentional resources available
Number of subjects: 0
Study 19364237 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) with depleted attentional resources
Number of subjects: 0
Study 19364237 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification task for CSs linked to US
Number of subjects: 0
Study 17319942 — intervention group
Group type: COMPARATOR
Intervention: Control group selected from Health Unit attenders
Number of subjects: 0
Study 17319942 — intervention group
Group type: COMPARATOR
Intervention: Control group selected from neighbourhood of cases
Number of subjects: 0
Study 15452182 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin-based)
Number of subjects: 5758
Study 12410926 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (local anesthesia to the trigger point)
Number of subjects: 60
Study 12410926 — intervention group
Group type: COMPARATOR
Intervention: Butylscopolamine (intravenous injection)
Number of subjects: 60
Study 9661636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load before surgery
Number of subjects: 18
Study 9661636 — intervention group
Group type: COMPARATOR
Intervention: No oral glucose load before surgery
Number of subjects: 18
Study 9661636 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion during post-op clamp
Number of subjects: 18
Study 9661636 — intervention group
Group type: COMPARATOR
Intervention: Pre-op clamp
Number of subjects: 18
Study 9661636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups post-surgery
Number of subjects: 18
Study 9661636 — intervention group
Group type: COMPARATOR
Intervention: Group not receiving glucose
Number of subjects: 18
Study 9098477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation procedure
Number of subjects: 45
Study 2651174 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg/day
Number of subjects: 144
Study 2651174 — intervention group
Group type: COMPARATOR
Intervention: Sustained release indomethacin 75 mg/day
Number of subjects: 144
Study 333568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sydnocarb (5-15 mg)
Number of subjects: 143
Study 333568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephexamid
Number of subjects: 143
Study 333568 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 143
Study 333568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 143
Study 333568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 31436551 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent-start peritoneal dialysis (USPD)
Number of subjects: 0
Study 28128973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load (HL) resistance training: 3 sets of 4-6 repetitions to momentary concentric failure
Number of subjects: 33
Study 28128973 — intervention group
Group type: COMPARATOR
Intervention: Low-load (LL) resistance training: 2 sets of 12-15 repetitions to momentary concentric failure
Number of subjects: 33
Study 26297572 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoticon placement (Green Smiley Face) next to healthful foods
Number of subjects: 297
Study 23357210 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 2872
Study 23357210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Doxazosin + Finasteride)
Number of subjects: 2872
Study 23357210 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2872
Study 23357210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2872
Study 22289552 — intervention group
Group type: COMPARATOR
Intervention: Continuous low-dose antibiotic (n = 37)
Number of subjects: 68
Study 22289552 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic (n = 31)
Number of subjects: 68
Study 19382094 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures and interventions for CMV and BKV infections
Number of subjects: 0
Study 17385106 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 42
Study 17385106 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 42
Study 15492046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive case management
Number of subjects: 3079
Study 15492046 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3079
Study 11700857 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9673754 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP chemotherapy followed by radiotherapy (RT) in CT-RT Group
Number of subjects: 184
Study 9673754 — intervention group
Group type: COMPARATOR
Intervention: RT alone in RT Group
Number of subjects: 184
Study 9673754 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP chemotherapy followed by RT in CT-RT Group (study 2)
Number of subjects: 184
Study 9673754 — intervention group
Group type: COMPARATOR
Intervention: RT alone in RT Group (study 2)
Number of subjects: 184
Study 9673754 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival at 48 months in CT-RT Group
Number of subjects: 184
Study 9673754 — intervention group
Group type: COMPARATOR
Intervention: Overall survival at 48 months in RT Group
Number of subjects: 184
Study 9673754 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated survival in CT-RT Group (study 2)
Number of subjects: 184
Study 9673754 — intervention group
Group type: COMPARATOR
Intervention: Estimated survival in RT Group (study 2)
Number of subjects: 184
Study 8082875 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg orally)
Number of subjects: 10
Study 8082875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2567266 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (2 g/day)
Number of subjects: 37
Study 2567266 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (3 g/day)
Number of subjects: 37
Study 31023432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish-oil supplementation of 2.5 g/day
Number of subjects: 65
Study 31023432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30021463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cristália enoxaparin (Ce)
Number of subjects: 243
Study 30021463 — intervention group
Group type: COMPARATOR
Intervention: Sanofi enoxaparin (Se)
Number of subjects: 243
Study 27658691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin-IPV
Number of subjects: 1200
Study 27658691 — intervention group
Group type: COMPARATOR
Intervention: Salk-IPV
Number of subjects: 1200
Study 25175097 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression care for people with lung cancer
Number of subjects: 142
Study 25175097 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study 21902859 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-(Z) lycopene-rich meal
Number of subjects: 6
Study 21902859 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals rich in 9-(Z) and 13-(Z) lycopene isomers
Number of subjects: 6
Study 21902859 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals rich in (all-E) lycopene
Number of subjects: 6
Study 19281006 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reconstruction of complex acetabular fractures (operated on the 7th or 10th day after injury)
Number of subjects: 191
Study 19281006 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reconstruction of complex acetabular fractures
Number of subjects: 191
Study 19281006 — intervention group
Group type: COMPARATOR
Intervention: Control group (operated on the 10th day after injury)
Number of subjects: 191
Study 19281006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 191
Study 17785037 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V (1 mg) + MPA (2.5 mg)
Number of subjects: 459
Study 17785037 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V (2 mg) + MPA (5 mg)
Number of subjects: 459
Study 17785037 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (E2V and MPA combinations)
Number of subjects: 459
Study 15097809 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated oral contrast (IOC)
Number of subjects: 30
Study 15097809 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 30
Study 15097809 — intervention group
Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 30
Study 11593367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupfeeding
Number of subjects: 56
Study 11593367 — intervention group
Group type: COMPARATOR
Intervention: Bottlefeeding
Number of subjects: 56
Study 9870472 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 15
Study 9870472 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 15
Study 7988628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 3 days)
Number of subjects: 12
Study 2686417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (200 mg every 12 hours)
Number of subjects: 32
Study 2686417 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime
Number of subjects: 32
Study 2686417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 32
Study 5134561 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 100
Study 5134561 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein test
Number of subjects: 100
Study 31930518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) based on Roy's adaptation model
Number of subjects: 0
Study 30707125 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask
Number of subjects: 319
Study 30707125 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 319
Study 30707125 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rebreathing mask
Number of subjects: 319
Study 30707125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 319
Study 28566193 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over M1‐SO
Number of subjects: 40
Study 28566193 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 25629544 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C (TTM33)
Number of subjects: 178
Study 25629544 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C (TTM36)
Number of subjects: 178
Study 23991658 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily or 30 mg once daily for specific patients)
Number of subjects: 4921
Study 23991658 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4921
Study 23991658 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 4921
Study 23991658 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (in patients with pulmonary embolism and right ventricular dysfunction)
Number of subjects: 4921
Study 23991658 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (in patients with pulmonary embolism and right ventricular dysfunction)
Number of subjects: 4921
Study 21911723 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg daily
Number of subjects: 667
Study 21911723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus octreotide (TAM-OCT) 90 mg depot monthly for 2 years
Number of subjects: 667
Study 17900778 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-resistant schizophrenia patients
Number of subjects: 0
Study 17900778 — intervention group
Group type: COMPARATOR
Intervention: Treatment-responsive chronic schizophrenia patients
Number of subjects: 0
Study 17900778 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 17214057 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Amifostine
Number of subjects: 67
Study 17214057 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 67
Study 14569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging (MPI)
Number of subjects: 105
Study 14569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal scintigraphy (ES)
Number of subjects: 105
Study 14569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac events
Number of subjects: 105
Study 14569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal dysfunction (ED)
Number of subjects: 105
Study 10791645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable poly‐L‐lactide lag screws (3 screws of 6.3 mm diameter)
Number of subjects: 40
Study 10791645 — intervention group
Group type: COMPARATOR
Intervention: Metallic screws (3 screws of 7 mm diameter)
Number of subjects: 40
Study 10791645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable poly‐L‐lactide lag screws
Number of subjects: 40
Study 10791645 — intervention group
Group type: COMPARATOR
Intervention: Metallic screws
Number of subjects: 40
Study 8783312 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (6 mg i.v.)
Number of subjects: 33
Study 8783312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8123107 — intervention group
Group type: EXPERIMENTAL
Intervention: National mammographic screening
Number of subjects: 0
Study 8123107 — intervention group
Group type: COMPARATOR
Intervention: Information circulated to general practitioners
Number of subjects: 0
Study 3730021 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol (Fluanxol) 0.5 mg, 1 mg, and 2 mg/day
Number of subjects: 107
Study 3730021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 28970207 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg/day and sulfasalazine 2000 mg/day (arm 1)
Number of subjects: 610
Study 28970207 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus adalimumab 40 mg/2 weeks (arm 2)
Number of subjects: 610
Study 28970207 — intervention group
Group type: EXPERIMENTAL
Intervention: Early remission group (387 patients)
Number of subjects: 610
Study 28970207 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (610 patients)
Number of subjects: 610